BRCA1 and colorectal carcinoma: CRC patients with BRCA2 mutations are significantly more common in the MSI-H than in the non-MSI-H cohort (37.6% vs 6.3%, p<0.0000001), and the same trend for BRCA1 mutations (27.7% vs 4.9%, p<0.0000001) (Figure 3B).